Drug Cardiovascular

Vyndaqel

Payments companies reported to CMS as associated with Vyndaqel. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$5.4Massociated payments (2023-2025)

21,669clinicians with associated payments

6companies reporting

By year

2023 $1.5M

2024 $1.5M

2025 $2.3M

Payments reported as associated with Vyndaqel, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Cardiovascular Disease $2.5M

Advanced Heart Failure and Transplant Cardiology $1.6M

Interventional Cardiology $259K

Family $169K

Internal Medicine $156K

Nurse Practitioner $95K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Vyndaqel

These are the largest totals companies reported as associated with Vyndaqel. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Christopher Pray	Bethel Park, PA	Cardiovascular Disease	$259,743.72
David Wolinsky	Weston, FL	Cardiovascular Disease	$132,720.24
Saurabh Malhotra	Buffalo, NY	Cardiovascular Disease	$110,483.84
David Snipelisky	Weston, FL	Advanced Heart Failure and Transplant Cardiology	$101,644.52
Vasvi Singh	Overland Park, KS	Cardiovascular Disease	$96,968.22
Roxana Ghashghaei	Laguna Hills, CA	Cardiovascular Disease	$95,312.99
Brendan Carry	Danville, PA	Advanced Heart Failure and Transplant Cardiology	$89,254.61
Edward Philbin	Albany, NY	Cardiovascular Disease	$86,270.77
Brett Sperry	Kansas City, MO	Advanced Heart Failure and Transplant Cardiology	$84,982.26
Allen Anderson	San Antonio, TX	Advanced Heart Failure and Transplant Cardiology	$82,056.48

Prescribed Vyndaqel?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.